advertiser banner advertiser banner advertiser banner advertiser banner
Digital Issues

Home >  E-Weekly >  January 21, 2014

New MRSA Test Gets FDA Nod

Published: January 20, 2014

A new MRSA test that helps you detect recently emerged strains has earned the Food and Drug Administration's market approval, says manufacturer BD Diagnostics.

The BD MAX MRSA XT Assay is the company's second test that can detect MRSA strains with the mecC gene, but the first that can do so via a nasal swab. The earlier version, released in 2013, could be used only on patients about to undergo surgery.

The test eliminates false positives produced by assays that detect S. aureus strains without certain genetic features, says the company, which can lead to expensive and unnecessary isolation of patients.

MRSA strains with the mecC gene account for nearly 3% of new MRSA cases in some areas, but can't be detected by all assays.

Jim Burger

 
Have an account? Please log in:
Email Address:
  Remember my login on this computer

DID YOU SEE THIS?
Infection Control

Bioburden Doesn't Stand a Chance

advertiser banner

Other Articles That May Interest You

Study Finds SSIs the Best Predictor of Surgical Readmissions

More than half of patients with SSIs return to hospital within 30 days.

Additional Skin Prepping Reduces SSIs

MRSA Decontamination Lowers SSI Risk in Ortho Cases